Vectura Share Discussion Threads

[fhmktg] 14/12/2017 09:50

Could feature in the year 2018 predictions over the holidays?

[a0148009] 14/12/2017 08:15

Taffy - Thanks good spot

[cumnor] 13/12/2017 21:48

Thanks, Taffy. This is a solid company in a great space-copd, asthma- with a huge potential market as SE Asian middle classes come on stream with their pulmonary problems over the next few years, and the income to buy. Totally undervalued. Reminds me of the old Axis Shield.

[taffy100] 13/12/2017 21:39

Market report: Vectura share price slump stokes takeover talk

[a0148009] 13/12/2017 19:37

Reminder :

Chippenham, UK - 14 November 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), announces that the Board has approved a share buyback to return up to GBP15 million of capital to shareholders. A purchase for cancellation programme of Vectura ordinary shares of GBP0.00025 each (the "Shares") will commence today up to a maximum consideration of GBP15 million over the next six months (the "Buyback").

The Group benefits from a strong capital position, with substantial cash of GBP90.5 million as at 30 June 2017, and multiple in-market drivers of long-term recurring revenue alongside a broad pipeline with significant future value potential also generating ongoing development service revenues from partnered projects. The Board believes that in addition to the implementation of the current investment strategy, the Buyback reflects strong financial management discipline and is an efficient allocation of capital.

Vectura has entered into an agreement with Numis Securities Limited ("Numis") on 13 November 2017 to enable Numis to use the maximum consideration of GBP15 million from today until a period expiring on 11 May 2018 to purchase Shares in accordance with the terms of the general authority to make market purchases of up to 67,872,000 of its Shares granted to Vectura by its shareholders at the 2017 Annual General Meeting held on 25 May 2017. The purpose of the Buyback is to reduce the share capital of Vectura and any Shares purchased will be cancelled.

Numis will make its trading decisions in relation to the Buyback independently of, and uninfluenced by, Vectura.

Any purchase of Shares pursuant to the agreement with Numis will be carried out on the London Stock Exchange and executed in accordance with Article 5(1) of Regulation (EU) No 596/2014, the Commission Delegated Regulation (EU) 2016/1052 and Chapter 12 of the Financial Conduct Authority's Listing Rules.

- Ends -

[dp1umb] 13/12/2017 17:30

Could this be the end of the buybacks??

[blueflex2] 13/12/2017 16:47

Up up up today. Over £1m in total spent on buyback in a month.

[a0148009] 13/12/2017 16:46

Very quiet on this BB, chart looks promising creeping up to 110, volumes reasonable
and good sign company purchases small which indicates genuine external investment
interest likely we have seen the bottom.

[jimboyce] 08/12/2017 16:37

Hooray, kept above 20 schillings.

[gbcol] 08/12/2017 15:17

Yes, it's had a few cracks at £1 this week but hasn't made it stick yet. Maybe today!

[dp1umb] 08/12/2017 15:14

A crazy end of week!

[top tips] 06/12/2017 09:34

IMMUPHARMA (IMM)

Small cap stock ImmuPharma finish Phase 3 for their potential blockbuster lupus drug Lupuzor in Q1 2018.

Based on the Phase 2b data and ongoing good safety in Phase 3, Lupuzor should easily beat the only competition GSK's lupus drug Benlysta, which has poor efficacy and adverse side effects.

Lupuzor is expected to achieve multi-billion dollar sales in lupus and could treat several other high value indications, adding to the value.

IMM currently 130p, estimated value £80+


Tim McCarthy (IMM Chairman) Presentation, 14/3/2017:

"There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug."

4 min 40 sec.



Resetting the Autoreactive Immune System with a Therapeutic Peptide in Lupus
Prof. Sylvian Muller
Lupus (2015) 24, pg 412–418

"The phase IIb trial showed that after three months of therapy (three subcutaneous injections of 200 ug peptide/patient in addition to standard of care), Lupuzor improved Systemic Lupus Erythematosus Disease Activity Index score of lupus patients under active treatment by 67.6% versus 41.5% in the placebo group (p<0.025). After three additional months of follow-up, the improvement rate was 84.2% versus 45.8% (p<0.025). The side effect profile was unproblematic and the drug was well tolerated as evidenced by a very low drop-out rate."

www.lupuzor.com/Documents/Schall%20Muller%20Lupus%202015.pdf

[blueflex2] 06/12/2017 09:32

Yes Joe, over 800k total spent so far

[popper joe] 06/12/2017 09:17

The £82k was spent on Monday this week. I believe they have spent a total of approx. £800k to-date.

[alexchry] 06/12/2017 09:05

Share buybacks seem nearer a million.

[blueflex2] 06/12/2017 09:03

£82k spent from £15m buyback until yesterday.

[rathean] 02/12/2017 14:56

Sold out at 99.1 Friday. Still think this has upside but more short term confidence elsewhere, will buy back in on a dip.

[rathean] 01/12/2017 09:22

Buy recommendation this morning, if we get through low 100s we could see 120 again before going sideways until news.

[saxula] 01/12/2017 09:07

I do love a bit of false hope

[diesel] 01/12/2017 08:44

Not sure we've broken the downtrend but does look interesting. Maybe the robot traders now see this as bullish.

[cityfarmer] 30/11/2017 16:38

That last trade looks like it was behind the rise? :-)

[pooroldboy55] 30/11/2017 13:40

NO cant but would be happy to let the wife stay, we have family in France so XMAS with them but after a few weeks with the grand children i need a holiday
cheers POB

[polaris] 30/11/2017 13:37

Hmmmm...might have taken my profit the other day here, but the share price is looking reasonably perky! These small changes are very lucrative for the margin trader when you are on the right side.

On the plus side, my 24002 DOW limit order was filled 1 month early (i only expected 24k in an optimal case with santa rally) closing the long so i can take stock of where it might go next. Almost 1000 points banked - tasty!

If only GSK would buck its trading socks up. I expected the lack of generic Advair erosion post Q3 results to pull it out of the, from my point of view, overdone falls. That is the one blight on my record and may well hit my stops and take the annual return back down to 45-50% area.

I'm still looking forward to earnings season in Jan/Feb as i think there will be some good trading opportunities.

[cityfarmer] 30/11/2017 13:31

VEC is spiking off the back of P.O.B holiday news- Incredible! P.O.B please confirm it’s a one way ticket? we may then hit £1 :-)

[pooroldboy55] 30/11/2017 13:15

Off on 19th December!!!!!!!!!!!!!!!!!